3ig6
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | + | {{Seed}} | |
+ | [[Image:3ig6.jpg|left|200px]] | ||
- | The | + | <!-- |
+ | The line below this paragraph, containing "STRUCTURE_3ig6", creates the "Structure Box" on the page. | ||
+ | You may change the PDB parameter (which sets the PDB file loaded into the applet) | ||
+ | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | ||
+ | or leave the SCENE parameter empty for the default display. | ||
+ | --> | ||
+ | {{STRUCTURE_3ig6| PDB=3ig6 | SCENE= }} | ||
- | + | ===Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-yloxy)-4-(3-dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2-yloxy]-4-dimethylamino-benzoic acid complex=== | |
- | Description: Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-yloxy)-4-(3-dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2-yloxy]-4-dimethylamino-benzoic acid complex | ||
- | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Oct | + | <!-- |
+ | The line below this paragraph, {{ABSTRACT_PUBMED_19703768}}, adds the Publication Abstract to the page | ||
+ | (as it appears on PubMed at http://www.pubmed.gov), where 19703768 is the PubMed ID number. | ||
+ | --> | ||
+ | {{ABSTRACT_PUBMED_19703768}} | ||
+ | |||
+ | ==Disease== | ||
+ | Known disease associated with this structure: Alzheimer disease, late-onset, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=191840 191840]] | ||
+ | |||
+ | ==About this Structure== | ||
+ | 3IG6 is a 4 chains structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3IG6 OCA]. | ||
+ | |||
+ | ==Reference== | ||
+ | <ref group="xtra">PMID:19703768</ref><references group="xtra"/> | ||
+ | [[Category: Homo sapiens]] | ||
+ | [[Category: U-plasminogen activator]] | ||
+ | [[Category: Adler, M.]] | ||
+ | [[Category: Whitlow, M.]] | ||
+ | [[Category: Blood coagulation]] | ||
+ | [[Category: Disulfide bond]] | ||
+ | [[Category: Egf-like domain]] | ||
+ | [[Category: Fibrinolysis]] | ||
+ | [[Category: Glycoprotein]] | ||
+ | [[Category: Hydrolase]] | ||
+ | [[Category: Kringle]] | ||
+ | [[Category: Pharmaceutical]] | ||
+ | [[Category: Phosphoprotein]] | ||
+ | [[Category: Plasminogen activation]] | ||
+ | [[Category: Polymorphism]] | ||
+ | [[Category: Protease]] | ||
+ | [[Category: S1 site inhibitor]] | ||
+ | [[Category: Secreted]] | ||
+ | [[Category: Selective]] | ||
+ | [[Category: Serine protease]] | ||
+ | [[Category: Structure-based drug design]] | ||
+ | [[Category: Urokinase]] | ||
+ | [[Category: Zymogen]] | ||
+ | |||
+ | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Oct 14 10:23:34 2009'' |
Revision as of 08:23, 14 October 2009
Contents |
Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-yloxy)-4-(3-dimethylamino-pyrrolidin-1-yl)-3,5-difluoro-pyridin-2-yloxy]-4-dimethylamino-benzoic acid complex
Template:ABSTRACT PUBMED 19703768
Disease
Known disease associated with this structure: Alzheimer disease, late-onset, susceptibility to OMIM:[191840]
About this Structure
3IG6 is a 4 chains structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.
Reference
- West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwe C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5712-5. Epub 2009 Aug 7. PMID:19703768 doi:10.1016/j.bmcl.2009.08.008
Page seeded by OCA on Wed Oct 14 10:23:34 2009
Categories: Homo sapiens | U-plasminogen activator | Adler, M. | Whitlow, M. | Blood coagulation | Disulfide bond | Egf-like domain | Fibrinolysis | Glycoprotein | Hydrolase | Kringle | Pharmaceutical | Phosphoprotein | Plasminogen activation | Polymorphism | Protease | S1 site inhibitor | Secreted | Selective | Serine protease | Structure-based drug design | Urokinase | Zymogen